The single-rod, etonogestrel-releasing, subdermal implant (ENG implant) is the most effective, long-acting reversible method of contraception available. The failure rate of the ENG implant is 0.05 ...
A woman in her late 30s presented with a complaint of not being able to palpate the subdermal contraceptive implant in her left arm, which was inserted 6 years earlier. An x-ray revealed a ...
Vivani Medical, Inc. VANI, on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight individuals.
NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in ...
ultra long-acting drug implants, today announced promising preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...
Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...